Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dejager

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Annales De Biologie Clinique|January 1, 1990
[Low density lipoprotein (LDL) heterogeneity and atherosclerosis]S Dejager, R Cohen, E Bruckert
Atherosclerosis|April 1, 1993
Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemiaE Bruckert, S Dejager, M J Chapman
Journal of Lipid Research|February 1, 1993
Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemiaS Dejager, E Bruckert, M J Chapman
Current Medical Research and Opinion|May 6, 2010
Role of vildagliptin in managing type 2 diabetes mellitus in the elderlyS Halimi, D Raccah, A Schweizer, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|April 11, 2008
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitusV Fonseca, M Baron, Q Shao, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|March 1, 1993
Oxidized low density lipoproteins bind to the scavenger receptor expressed by rabbit smooth muscle cells and macrophagesS Dejager, M Mietus-Synder, R E Pitas
Diabetes & Metabolism|December 3, 2014
The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice?L Monnier, C Colette, S Dejager, et al.
Diabetes Research and Clinical Practice|April 17, 2014
Residual dysglycemia when at target HbA(1c) of 7% (53mmol/mol) in persons with type 2 diabetesL Monnier, C Colette, S Dejager, et al.
Journal of Internal Medicine|September 25, 1998
Sheehan's syndrome: differential diagnosis in the acute phaseS Dejager, S Gerber, L Foubert, et al.
Annales D'Endocrinologie|January 1, 1997
[Lipid risk factors of atherosclerosis: who, when, how to treat?]L Foubert, S Dejager, E Bruckert, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Annales De Biologie Clinique|January 1, 1990
[Low density lipoprotein (LDL) heterogeneity and atherosclerosis]S Dejager, R Cohen, E Bruckert
Atherosclerosis|April 1, 1993
Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemiaE Bruckert, S Dejager, M J Chapman
Journal of Lipid Research|February 1, 1993
Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemiaS Dejager, E Bruckert, M J Chapman
Current Medical Research and Opinion|May 6, 2010
Role of vildagliptin in managing type 2 diabetes mellitus in the elderlyS Halimi, D Raccah, A Schweizer, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|April 11, 2008
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitusV Fonseca, M Baron, Q Shao, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|March 1, 1993
Oxidized low density lipoproteins bind to the scavenger receptor expressed by rabbit smooth muscle cells and macrophagesS Dejager, M Mietus-Synder, R E Pitas
Diabetes & Metabolism|December 3, 2014
The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice?L Monnier, C Colette, S Dejager, et al.
Diabetes Research and Clinical Practice|April 17, 2014
Residual dysglycemia when at target HbA(1c) of 7% (53mmol/mol) in persons with type 2 diabetesL Monnier, C Colette, S Dejager, et al.
Journal of Internal Medicine|September 25, 1998
Sheehan's syndrome: differential diagnosis in the acute phaseS Dejager, S Gerber, L Foubert, et al.
Annales D'Endocrinologie|January 1, 1997
[Lipid risk factors of atherosclerosis: who, when, how to treat?]L Foubert, S Dejager, E Bruckert, et al.
Pageof 5